S‐1 plus cisplatin as first‐line treatment of patients with advanced non‐small cell lung cancer in Taiwan

Abstract

Aim S‐1 combined with cisplatin is known to be noninferior to taxanes plus platinum as the first‐line treatment for patients with advanced nonsmall cell lung cancer (NSCLC) in the Japanese population. This study aimed to evaluate the efficacy and safety profiles of oral S‐1 plus cisplatin (SP) in Taiwanese patients. Methods Patients with previously untreated stage IIIB or IV NSCLC were prospectively recruited to receive 40‐60 mg of S‐1 twice daily on days 1‐21 plus 60 mg/m2 of cisplatin on day 8 in a 5‐week cycle for up to six cycles. Results A total of 55 patients from five cancer centers in Taiwan were enrolled. Among the 46 evaluable patients, those administered with SP achieved disease control rate of 69.6% (partial response, 19.6%; stable disease, 50.0%), with median overall survival and progression‐free survival (PFS) of 15.1 and 5.7 months, respectively. Moreover, a better survival trend was observed in epidermal growth factor receptor mutation‐positive patients versus mutation‐negative patients treated with SP (PFS, 8.6 vs 5.6 months). The most commonly observed treatment‐related adverse events (AEs) were nausea (41.8%), followed by decreased appetite, anemia, and diarrhea. Grade of ≥3 AEs related to the study treatment occurred in 11 patients (20.0%). No febrile neutropenia or treatment‐related death was found in this study. Conclusions This study demonstrated that SP is an effective and safe first‐line regimen for Taiwanese patients with advanced NSCLC.

Overweight and Obesity are Associated with Poorer Survival Among Patients with Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

“…This finding was in line with the previous studies both in the western world settings 7 and in an Asian country. 6 However, the overall response rate to chemotherapy in the present study was higher compared to the other studies in patients with advanced stage NSCLC receiving platinum-based chemotherapy globally 21 and in Asia (42% in this study, 20% in a Taiwanese study, 27% in a Japanese study), 6 , 22 despite similar age, sex, and tumor histopathology distribution. This finding suggests that geographical area or ethnicity might to some extent affect the treatment response.…”

Knockdown of miR-15b partially reverses the cisplatin resistance of NSCLC through the GSK-3β/MCL-1 pathway

“…Furthermore, cisplatin is still used as the first-line chemotherapeutic drug for patients with advanced NSCLC. 10 However, clinical application of cisplatin is limited by harsh side effects including nephrotoxicity, ototoxicity, neurotoxicity, bone marrow suppression, and digestive reaction. 11 Given this, combined treatment with sensitizing agents is desirable to increase the sensitivity of tumor cells to cisplatin.…”